Our Success

Salarius Pharmaceuticals Rings the Bell at NASDAQ

In July 2019, Salarius Pharmaceuticals (NASDAQ: SLRX) completed a successful reverse merger with Flex Pharma, marking a pivotal milestone in the company’s growth trajectory and transition to the public markets.

This outcome was the result of strategic execution by senior management, an engaged Board, and leading investment banking partners—supported by a world-class scientific team and advisory group that advanced the company’s lead candidate, Seclidemstat, into Phase 1/2 clinical development.

The listing enabled Salarius to access capital through equity lines and shelf registrations (S-1 / S-3), ultimately raising over $40 million as a public company to support ongoing clinical trials and corporate expansion.

👉 Salarius Rings the Bell at NASDAQ - (press release)